These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19224904)

  • 1. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    O'Mahony R; Richards A; Deighton C; Scott D
    Ann Rheum Dis; 2010 Oct; 69(10):1823-6. PubMed ID: 19224904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott IC; Kingsley GH; Scott DL
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
    Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
    Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review.
    Calvo Alén J; Pérez T; Romero Yuste S; Ferraz-Amaro I; Alegre Sancho JJ; Pinto Tasende JA; Maceiras Pan F; Quevedo JC; Hernández-Hernández MV; Hidalgo Calleja C; San Martín Álvarez A; Sánchez MIT; Sanmartí R
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):324-332. PubMed ID: 30241955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
    Graudal N; Jürgens G
    Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.
    Verstappen M; van Mulligen E; de Jong PHP; van der Helm-Van Mil AHM
    RMD Open; 2020 May; 6(1):. PubMed ID: 32393523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study.
    Kyburz D; Gabay C; Michel BA; Finckh A;
    Rheumatology (Oxford); 2011 Jun; 50(6):1106-10. PubMed ID: 21258051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
    Paulus HE; Di Primeo D; Sharp JT; Genant HK; Weissman BN; Weisman MH; Sanda M;
    J Rheumatol; 2004 Mar; 31(3):470-81. PubMed ID: 14994390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
    Pincus T; Yazici Y; Sokka T; Aletaha D; Smolen JS
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S179-85. PubMed ID: 14969073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year.
    Verstappen SM; Jacobs JW; Bijlsma JW; Heurkens AH; van Booma-Frankfort C; Borg EJ; Hofman DM; van der Veen MJ;
    Arthritis Rheum; 2003 Jul; 48(7):1797-807. PubMed ID: 12847672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.